immune therapy is emerging line and we should be aware of its toxicity and management 8/2019

1. Immunotherapy side
effects management
Presented by :
HebatAllah Mahmoud Bakri
ASS. Lecturer clinical oncology
department

2. Agenda :
• 1- what is immunotherapy and MOA
• B- Prons and cones of immunotherapy
• C- IRAE ( def. . Causes , types , general principle in management )
• D- in details ( colitis – pneumonitis – hypophysitis )
• 2- - CAR T CELL ( def. , MOA, uses , adverse events (CRS IN DETAILS )
• 3- - summary

8. • Def :
A type of drug that blocks certain proteins checkpoint proteins found on
T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2 which
help in keeping immune responses in check and can keep T cells from
killing cancer cells
• So , the “brakes” on the immune system are released and T cells are
able to kill cancer cells better
Immune check point inhibitors

11. Prons and cons of immune checkpoint inhibitors
• 1- durable responses and generally fewer adverse effects than
conventional chemo- therapy
• 2- immune-related adverse events (irAEs) can be life-threatening Early
recognition of irAEs and initiation of treatment are critical to reduce
morbidity.

12. Causes of irAEs :

16. time and event

20. 1 – colitis

23. 2- Penumonitis

24. 3- hypophysitis

27. def of pseudoprogression
: tumor growth from
treatment effect rather
than true disease
progression, has been
described with immune
checkpoint inhibitors.

31. CAR T- CELL IMMUNOTHERAPY

47. • More experience is needed for better evaluation of
imaging in patients taking immunotherapy
• Rapid management once IARE grading known as it
might be fatal (corticosteroids are corner stone )
• CAR-T – CELL is anew immunotherapy tool used in ttt
with different toxicity profile most important is CRS